VolitionRx mid-year: Vet test in 15 countries, $23M milestones, human license target H2 2024

VOLITIONRX LTD

Nu.Q Vet Cancer Test now available in 15 countries via Antech, IDEXX, Fujifilm; aiming to triple 2023 test sales of 58,000.
Received $23M in upfront and milestone payments from Heska (Antech) for veterinary test.
Preparing data rooms for Nu.Q NETs, Nu.Q Lung, and Capture-PCR technologies; first human licensing deal targeted in H2 2024.
Capture-PCR method for direct ctDNA detection submitted for peer review July 2024; early-stage cancer discrimination demonstrated.
Active commercial discussions with major liquid biopsy, IVD, and oncology players.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.